Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
01/19/20174:27PMDJNRival to EpiPen Allergy Treatment to Return to Market--Update
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products. Privately held Kaleo, the maker of the Auvi-Q injectors, said it had corrected the manufacturing problems that triggered a recall... More...>>
01/19/20173:17PMDJNRival to EpiPen Allergy Treatment to Return to Market
By Jonathan D. Rockoff The maker of an EpiPen rival said its emergency allergy treatment would return to the market on Feb. 14, adding more competition to the market for the costly products. Privately held Kaleo, the maker of the Auvi-Q injectors, said it had corrected the manufacturing problems that triggered a recall... More...>>
01/12/20175:03PMDJNCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
By Anne Steele and Joseph Walker A top U.S. health insurer has dropped its coverage of Mylan NV's brand-name EpiPen and switched to the half-priced version Mylan launched in response to public outrage over its sharp price increases on the lifesaving drug. Cigna Corp. swapped its coverage of the $600 EpiPen for Mylan's... More...>>
01/12/201712:49PMDJNCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic
By Anne Steele A top U.S. health insurer has dropped its coverage of Mylan NV's EpiPen and switched to its generic alternative, following public outrage over sharp price increases for the lifesaving drug. Cigna Corp. swapped its coverage of the $600 EpiPen for Mylan's half-priced generic version, according to... More...>>
01/11/20178:00AMPRNUSU.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab If Approved, MYL-1401O Has Potential To Be the First Biosimilar Trastuzumab in the U.S. PR Newswire HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Jan. 11, 2017 HERTFORDSHIRE, England, PITTSBURGH and BENGALURU... More...>>
01/09/20178:45AMPRNUSMylan to Present at the 35th Annual J.P. Morgan Healthcare Conference
Mylan to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that CEO Heather Bresch will present at the 35th Annual J.P. Morgan Healthcare... More...>>
01/09/20177:30AMPRNUSMylan Acquires Cold-EEZE® Brand to Further Expand OTC Business
Mylan Acquires Cold-EEZE® Brand to Further Expand OTC Business PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 HERTFORDSHIRE, England and PITTSBURGH, Jan. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has agreed to acquire global rights to Cold-EEZE® brand cold remedy... More...>>
12/29/20164:23PMPRNUSMylan Launches Generic Concerta® Tablets
Mylan Launches Generic Concerta® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36... More...>>
12/29/20167:00AMPRNUSMylan Launches Generic Cerebyx® Injection
Mylan Launches Generic Cerebyx® Injection PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Fosphenytoin Sodium Injection USP, 75 mg/mL, (50 mg PE*/mL), packaged in 100... More...>>
12/28/20164:33PMPRNUSMylan Launches Generic Zovia® Tablets
Mylan Launches Generic Zovia® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 28, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP, 1 mg / 0.05 mg. Mylan's... More...>>
12/27/20168:00AMPRNUSJournal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data
Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data HERITAGE Study Results Demonstrate Equivalent Overall Response Rate for MYL-1401O in Comparison to Branded Trastuzumab PR Newswire HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Dec... More...>>
12/16/20168:01AMPRNUSMylan Launches the First Generic for EpiPen® (epinephrine injection, USP) Auto-Injector as an Authorized Generic
Mylan Launches the First Generic for EpiPen® (epinephrine injection, USP) Auto-Injector as an Authorized Generic Authorized Generic Offered at More Than 50% Below Wholesale Acquisition Cost of EpiPen Auto-Injector PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 16, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec... More...>>
12/09/201610:50PMBWMYLAN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General & Kahn Swick & Foti, LLC Remin...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until December 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Mylan N.V. (NasdaqGS: MYL). Investor... More...>>
12/05/20164:31PMPRNUSRosen Law Firm Reminds Mylan N.V. Investors of Important Dec. 12 Deadline in Class Action Filed by Firm - MYL
Rosen Law Firm Reminds Mylan N.V. Investors of Important Dec. 12 Deadline in Class Action Filed by Firm - MYL PR Newswire NEW YORK, Dec. 5, 2016 NEW YORK, Dec. 5, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Mylan Inc., predecessor of Mylan N.V., and/or... More...>>
12/01/20161:34PMBWThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Mylan NV Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Mylan N.V. (“Mylan” or the “Company”) (NASDAQ: MYL) securities between February 28, 2013 and October 7, 2016, inclusive (the “Class Period”). Mylan investors have until December 12, 2016 to... More...>>
12/01/20169:37AMPRNUSMylan's Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever
Mylan's Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2016 HERTFORDSHIRE, England and PITTSBURGH, Dec. 1, 2016 /PRNewswire/ -- Today, Mylan N.V. (NASDAQ, TASE: MYL) joins people worldwide in recognizing World AIDS Day. Observed every Dec. 1, the... More...>>
11/28/20167:30AMPRNUSMylan Signs Sub-license Agreement with the Medicines Patent Pool to Increase Access to Hepatitis C Treatment in Developing Co...
Mylan Signs Sub-license Agreement with the Medicines Patent Pool to Increase Access to Hepatitis C Treatment in Developing Countries PR Newswire HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
11/25/201611:34AMPRNUSSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Mylan N.V...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Mylan N.V. To Contact The Firm Before Lead Plaintiff Deadline PR Newswire NEW YORK, Nov. 25, 2016 NEW YORK, Nov. 25, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm... More...>>
11/18/201611:45PMBWDEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Lo...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Mylan N.V. (Nasdaq: MYL) (“Mylan” or the “Company”) securities during the... More...>>
11/18/201610:07PMBWMYLAN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess ...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Mylan N.V. (NasdaqGS: MYL), if they purchased the Company’s securities... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V:us D:20170120 20:04:53